

Ref: MHL/Sec&Legal/2021-22/02

Date: April 8, 2021

To,

**Head, Listing Compliance Department
BSE Limited**

Phiroze Jeejeebhoy Towers Dalal Street,
Mumbai - 400 001.

**Head, Listing Compliance Department
National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400051

Scrip Code: 542650

Scrip Symbol: METROPOLIS

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

In accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 and Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information in terms of Regulation 8 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, we would like to update on the following key business parameters of the Company on a Consolidated basis for the quarter ended March 31, 2021 i.e. Q4FY21:

Covid-19 lockdowns impacted business in the second half of March, 2020. Hence, Q4FY21 quarter is not directly comparable to Q4FY20 and therefore the business performance has to be viewed keeping that in consideration.

1. The Company has achieved a revenue growth of ~40% YoY in Q4FY21 as compared to Q4FY20. Non-Covid Business revenue increased by ~21% YoY in Q4FY21 as compared to Q4FY20.
2. In spite of conducting higher Covid Tests on QoQ basis, Covid Business revenue (RT-PCR Tests) stood at ~14% of total revenue in Q4FY21 as compared to 19% in Q3FY21 due to reduction in Test prices by Government agencies.
3. The Company recorded highest ever monthly revenue in March 2021 on the back of strong growth in Non-covid business coupled with an uptick in covid business.
4. No. of Patient Visits for Q4FY21 increased by ~30% YoY to 3.18 Mn as compared to 2.45 Mn in Q4FY20 and 2.67 Mn in Q3FY21.
5. No. of Tests for Q4FY21 increased by ~24% YoY to 6.50 Mn as compared to 5.26 Mn in Q4FY20 and 5.12 Mn in Q3FY21.

BLOOD TESTS • DIAGNOSTICS • WELLNESS

METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.
CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

6. On-account of strong revenue growth, better tests mix, cost optimization efforts and improved operational efficiencies, EBITDA margins continue to remain at healthy levels in Q4FY21.
7. The Company continues to be a Net Cash Company. After payment of Interim Dividend and other regulatory charges and taxes thereof during Q4FY21, the Cash and Cash equivalents of the Company stood at over Rs. 370 Crores as at March 31, 2021

The above information is as per limited review by the Management Team.

This is for your information and also for the information of your members and the public at large.

Yours Faithfully

For **Metropolis Healthcare Limited**



Poonam Tanwani

Company Secretary & Compliance Officer

Membership No. A19182

BLOOD TESTS • DIAGNOSTICS • WELLNESS

METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.

CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.